Alendronate — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Osteoporosis

• Ibandronate
• Raloxifene
• Risedronate

Other medications in Musculoskeletal

• Allopurinol
• Celecoxib
• Colchicine
• Diclofenac
• Febuxostat
• Indomethacin
• Meloxicam
• Naproxen

About Alendronate

Alendronate is a widely prescribed medication crucial for maintaining strong bones and preventing fractures, especially for those at risk of osteoporosis. If you've been prescribed alendronate, understanding its benefits and how to manage costs is key.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Alendronate is approved for (FDA label)

Alendronate sodium is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women ( 1.1 , 1.2 ) Treatment to increase bone mass in men with osteoporosis ( 1.3 ) Treatment of glucocorticoid-induced osteoporosis ( 1.4 ) Treatment of Paget's disease of bone ( 1.5 ) Limitations of use : Optimal duration of use has not been determined. For patients at low- risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.6 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets, USP are indicated for the treatment of osteoporosis in postmenopausal women.

Source: Read the full FDA label on DailyMed. Label effective date: July 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Alendronate (FDA label)

Alendronate Sodium Tablets, USP 35 mg are white, capsule shaped, biconvex tablets debossed with 'C223' on one side and plain on the other side. Tablets: 35mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: c7e470d6-508e-466e-a78d-060bbbc9745c. SPL document ID: 55b5e077-d254-8e68-e063-6294a90aebcb. Label effective date: July 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Alendronate (FDA label)

The following clinically significant adverse drug reactions are described elsewhere in the labeling: Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1) Mineral Metabolism [see Warnings and Precautions (5.2)] Musculoskeletal Pain [see Warnings and Precautions (5.3)] Osteonecrosis of the Jaw [see Warnings and Precautions (5.4)] Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5)] Renal Impairment [see Warnings and Precautions (5.6)] Glucocorticoid-Induced Osteoporosis [see Warnings and Precautions (5.7)] Most common adverse reactions (greater than or equal to 3%) are abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd., India at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: c7e470d6-508e-466e-a78d-060bbbc9745c. SPL document ID: 55b5e077-d254-8e68-e063-6294a90aebcb. Label effective date: July 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Alendronate (FDA label)

Alendronate sodium tablets are contraindicated in patients with the following conditions: Inability to stand or sit upright for at least 30 minutes [see Dosage and Administration ( 2.6 ); Warnings and Precautions ( 5.1 )] Hypocalcemia [see Warnings and Precautions ( 5.2 )] Hypersensitivity to any component of this product. Hypersensitivity reactions including urticaria and angioedema have been reported [see Adverse Reactions ( 6.2 )] . Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see Warnings and Precautions ( 4 , 5.1 )] Inability to stand/sit upright for at least 30 minutes ( 2.6 , 4 , 5.1 ) Hypocalcemia ( 4 , 5.2 ) Hypersensitivity to any component of this product ( 4 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: c7e470d6-508e-466e-a78d-060bbbc9745c. SPL document ID: 55b5e077-d254-8e68-e063-6294a90aebcb. Label effective date: July 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Alendronate (FDA label)

Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or worsening symptoms occur. ( 5.1 ) Hypocalcemia can worsen and must be corrected prior to use. ( 5.2 ) Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. ( 5.3 ) Osteonecrosis of the Jaw has been reported. ( 5.4 ) Atypical Fractures Including Femoral Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered ( 5.5 ) 5.1 Upper Gastrointestinal Adverse Reactions Alendronate sodium, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa.

Source: FDA prescribing information (DailyMed). Set ID: c7e470d6-508e-466e-a78d-060bbbc9745c. SPL document ID: 55b5e077-d254-8e68-e063-6294a90aebcb. Label effective date: July 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Alendronate (FDA label)

Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2.6 , 7.1 ) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7.2 , 7.3 ) 7.1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7.2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate sodium greater than 10 mg and aspirin-containing products. 7.3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSAIDs).

Source: FDA prescribing information (DailyMed). Set ID: c7e470d6-508e-466e-a78d-060bbbc9745c. SPL document ID: 55b5e077-d254-8e68-e063-6294a90aebcb. Label effective date: July 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.